


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中生北控生物科技股份有限公司
BIOSINO BIO-TECHNOLOGY AND SCIENCE INCORPORATION

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 8247)

ANNOUNCEMENT

**(I) PROPOSED APPOINTMENT OF
INDEPENDENT NON-EXECUTIVE DIRECTOR; AND
(II) PROPOSED APPOINTMENT OF SUPERVISOR**

Reference is made to the announcement of Biosino Bio-Technology and Science Incorporation (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 26 April 2024 (the “**Announcement**”) in relation to the resignation of Mr. Li Jifeng (李繼峰) (“**Mr. Li**”) as a shareholder representative supervisor of the Company (the “**Supervisor(s)**”) and the chairman of the supervisory committee of the Company (the “**Supervisory Committee**”). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as those defined in the Announcement.

PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

In accordance with the relevant requirements of the Company Law of the PRC and Article 98 of the Articles of Association of the Company, Dr. He Xin (何欣) (“**Dr. He**”) was nominated by Jingning Guoke Kangyi Enterprise Management Center LLP* (景寧國科康儀企業管理中心(有限合夥)) (“**Jingning Guoke**”), a shareholder of the Company (the “**Shareholder(s)**”) holding approximately 7.83% of the Company’s issued share capital, as a candidate for an independent non-executive Director and shall propose to the forthcoming annual general meeting of the Company to be held on 28 June 2024 (the “**AGM**”) for consideration. If appointed, the term of office shall be from the date of approval at the AGM to the expiration of the current session of the Board.

The biographical details of Dr. He are set out below:

Dr. He, aged 52, obtained a Doctor of Philosophy in Immunobiology from Yale University in 2003. She has more than 20 years of experience in healthcare enterprise operations, international business development and investment. Dr. He was the founder and the chief executive officer of RHEI Pharmaceuticals, Inc., which is a fully integrated specialty pharmaceuticals company. She was also a partner of Columbus Growth, LLC and a senior partner of Beijing Dinghui Innovative Investment Consultant Co. Ltd.* (北京鼎暉創新投資顧問有限公司). Dr. He is currently a managing partner of Ningbo Huiding Cornerstone Investment Management Co. Ltd.* (寧波匯鼎基石投資管理有限公司).

Dr. He has confirmed that (i) she met the independence criteria as set out in Rule 5.09 of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”); (ii) she has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the GEM Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment.

As at the date of this announcement, save as disclosed above, Dr. He (i) has not held any other position in the Company or other subsidiaries; (ii) has not held any directorship in other listed companies in the last three years and has no other major appointments or professional qualifications; and (iii) does not have any relationships with any Directors, Supervisors, senior management, substantial shareholders or controlling shareholders of the Company. Dr. He does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The Company has yet to fix the remuneration of Dr. He. The Board will consider the duties of Dr. He in the Company with reference to the remunerations of other Directors in determining the remuneration of Dr. He.

The Board is not aware that there are any other matters relating to the appointment of Dr. He that need to be brought to the attention of the Shareholders and there is no other information relating to Dr. He which is required to be disclosed pursuant to any of the requirements of Rule 17.50(2) of the GEM Listing Rules.

The proposed appointment of Dr. He will bring valuable diversity to the Board, and the Company will fulfil the gender diversity requirement under Rule 17.104 of GEM Listing Rules following her appointment.

PROPOSED APPOINTMENT OF SUPERVISOR

As disclosed in the Announcement, the resignation of Mr. Li will take effect after the election of a new Supervisor at a general meeting to be convened and held by the Company.

The Board hereby announces that, based on the recommendation of Jingning Guoke and after deliberation of the Supervisory Committee, it is proposed to appoint Mr. Fan Hua (范華) (“**Mr. Fan**”) as a shareholder representative Supervisor and the chairman of the Supervisory Committee.

The biographical details of Mr. Fan are set out below:

Mr. Fan, aged 60, graduated from Accounting Profession from Sichuan Radio and TV University (currently named as The Open University of Sichuan) in 1986 and is a Chinese Certified Public Accountant. He has been engaged in finance and management works for more than 30 years and is currently the general manager of Sichuan Guoke Kangyi Medical Equipment Co., Ltd.* (四川國科康儀醫療器材有限公司).

As at the date of this announcement, save as disclosed above, Mr. Fan (i) has not held any other position in the Company or other subsidiaries; (ii) has not held any directorship in other listed companies in the last three years and has no other major appointments or professional qualifications; and (iii) does not have any relationships with any Directors, Supervisors, senior management, substantial shareholders or controlling shareholders of the Company. Mr. Fan does not have any interests in the shares of the Company within the meaning of Part XV of the SFO.

The Company has yet to fix the remuneration of Mr. Fan. The Board will consider the duties of Mr. Fan in the Company with reference to the remunerations of other Supervisors in determining the remuneration of Mr. Fan.

The Board is not aware that there are any other matters relating to the appointment of Mr. Fan that need to be brought to the attention of the Shareholders and there is no other information relating to Mr. Fan which is required to be disclosed pursuant to any of the requirements of Rule 17.50(2) of the GEM Listing Rules.

The appointments of Mr. Fan as a shareholder representative Supervisor and the chairman of the Supervisory Committee are subject to the passing of an ordinary resolution in relation to the proposed appointment of Mr. Fan as a Supervisor by the Shareholders at the AGM. If appointed, the term of office shall be from the date of approval at the AGM to the expiration of the current session of the Supervisory Committee.

GENERAL MEETING

A general meeting will be convened to seek the Shareholders' approval for, among other things, (i) the appointment of Dr. He as an independent non-executive Director; and (ii) the appointment of Mr. Fan as a Supervisor.

A supplemental circular containing, among other things, (i) the proposed appointment of Dr. He as an independent non-executive Director; (ii) biographical details and other relevant information of Dr. He; (iii) the proposed appointment of Mr. Fan as a Supervisor; (iv) biographical details and other relevant information of Mr. Fan; and (v) a supplemental notice of the AGM, will be despatched to the Shareholders as soon as practicable.

* *For identification purposes only*

For and on behalf of the Board
Biosino Bio-Technology and Science Incorporation
Wu Lebin
Chairman and Executive Director

Beijing, the PRC, 12 June 2024

As at the date of this announcement, the Board comprises:

Chairman and executive Director

Mr. Wu Lebin (吳樂斌先生)

Vice chairmen and non-executive Directors

Mr. Yang Peng (楊鵬先生) and Mr. Chen Zhengyong (陳正永先生)

President and executive Director

Mr. Chen Peng (陳鵬先生)

Non-executive Directors

Mr. Li Zhonghua (李忠華先生) and Dr. Gao Guangxia (高光俠博士)

Independent non-executive Directors

Prof. Shen Zuojun (沈佐君教授), Mr. Lu Qi (陸琪先生) and Prof. Shen Jiangan (沈劍剛教授)

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, (1) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (2) there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the website of the Stock Exchange at www.hkexnews.hk for at least 7 days from the date of its posting and on the website of the Company at www.zhongsheng.com.cn.